Fluicell represents a new paradigm in therapeutics. Our Nexocyte™ tissue production platform pushes the boundary of what is possible within regenerative medicine and drug development, enabling completely new ways to treat disease.
Chronic disorders related to tissue damage, including cardiac, pulmonary, kidney and metabolic disorders, are among the diseases responsible for the most deaths around the world. With our tissue production platform, we are unlocking new ways to treat these diseases, offering ways to create therapies that can improve the lives of millions of patients worldwide.
Fluicell’s Nexocyte platform is based on twenty years of R&D and combines our high-resolution bioprinting technology with state-of-the-art biomaterials and tissue design tools and know-how. The unique technology makes it possible to control tissue formation down to the level of individual cells.
No matter whether the goal is to create tissue-based therapeutic applications or human screening products, our platform can deliver detailed tailored tissue-based solutions, targeting any disease area and using any cell type.
Unlock therapeutics with Nexocyte tailored tissues
The ability to create tissues using any cell type with single-cell precision opens a whole new world of possibilities for regenerative medicine and drug development. With our Nexocyte platform, the possibilities for design-driven tissue engineering are almost endless.
At the core of the platform is Fluicell’s bioprinting technology Biopixlar, which makes it possible to build functional tissues directly using the cells you want – without the need for any bioink or other carrier material. Thanks to its high-precision cell deposition technology, you can bring your detailed tissue designs to life without having to compromise. The high-resolution bioprinting capacity makes it possible to place cells close to each other, ensuring efficient cell-to-cell communication.
Watch: PRINTING WITH BIOPIXLAR
Engineered pancreatic islets containing alpha and beta cells, printed on biomaterial substrate using Biopixlar.
Bioprinted liver model
The liver plays a central role during drug development because of its function in drug metabolization. We have used Biopixlar to create a bioprinted composite in vitro model that improves the hepatocyte function compared to conventional cell culture. The 3D liver model is quick to assemble and easy to scale up to allow parallel bioassays. The composite liver model features detailed arrangements of hepatocytes and fibroblasts that help to promote hepatocyte functionality. The detailed patterning is made possible by Biopixlar’s high-precision cell deposition capabilities. Read our application note on bioprinted liver models:
Brioprinted breast cancer models
Faithfully replicating the tumor microenvironment is crucial for better understanding of cancer development. We have used our Biopixlar platform to position cells directly onto human-derived breast cancer tumors, without the use of any additional biomaterials. This creates a powerful cancer research model that closely mimics the structural and biological complexity of actual tumors. This novel approach to producing tumor models unlocks the possibility for complex studies on cell and tumor microenvironment, cell and immune cell interactions, cancer cell invasion, and drug toxicity. Read our application note, “Human de-cellularized tumors as bioprinting scaffolds”:
Islet organoid bioprinting
At Fluicell, we use the power of Biopixlar to develop artificial pancreatic islets that consist of a combination of alpha, beta and support cells, facilitating full euglycemic control. In the production of islets, we rely on Biopixlar’s capacity for precise cell placement to produce islets with a size and composition that resemble the native Islets of Langerhans. Read more about Fluicell’s ongoing development of tissue-based type 1 diabetes therapeutics in our white paper:
Spheroids are a powerful tool for in vitro tissue and disease modeling, with multiple applications across cancer and stem cell research and drug development. With Biopixlar, you can create spheroids to fit your research needs. Biopixlar’s microfluidic high-precision cell deposition technology lets you control both the size and the cellular composition of the spheroids. Since you perform cell printing directly in culture media without any bioink, cell survivability inside the spheroids is high. Read our application note on Biopixlar spheroid bioprinting:
Biopixlar’s direct cell deposition technology can be used to create cell arrays, enabling you to set up assays and study biological processes in great detail. The precise cell placement controls make it possible to create arrays ranging from groups of cells to individual cells. Read about the research at the Knight Cancer Precision Biofabrication Hub, which uses Biopixlar to study cancer development on a single-cell level:
Controlling the cell microenvironment is crucial for ensuring proper tissue function. With Fluicell’s Biopixlar technology cells can be arranged with microscopic precision directly in solution, making it possible to go directly from tissue design to precise assembly. The high-resolution bioprinting capacity makes it possible to place cells right next to each other with high level of microenvironment control, ensuring efficient cell to cell communication. Read our application note on cell microenvironment design:
Biopixlar® single-cell bioprinting
Biopixlar is a completely new type of bioprinter with the unique capability to position cells in three dimensions with high resolution and precision without the use of bioink. Based on innovative Fluicell technology, Biopixlar is capable of generating detailed, multicellular biological tissues, directly in cell culture media.
Biopixlar lets you print even the most demanding cell types in any configuration, from single-cell arrays to organoids and complex tissues. The high-precision microfluidic cell deposition technology promotes intercellular communication and ensures high cell viability.
Biopixlar has been used to print hepatocytes, beta cells, cardiomyocytes, T-cells, primary neurons, IPSCs, MSCs, corneal cells, melanoma and adenocarcinoma cells, neuroblastomal cells, fibroblasts, renal epithelial cells, keratinocytes, and much more.
Fluicell has developed research tools based on our unique microfluidic technology that make it possible to study individual cells directly in their native environment and to perform biological assays with high precision.
Our single-cell toolbox contains the devices BioPen, Biozone 6 and Dynaflow Resolve. The devices add a wide range of capabilities to our Nexycyteplatform, including localized drug delivery, dose response assays andsingle-cell analysis. Fluicell's single-cell technologies work with any cell type and require very little material, making them ideal for scarce and valuable samples.
Fluicell’s tissue engineering technology is covered by a broad IP platform, focused on controlling liquid flows, cells and biology with high precision. Our IP strategy is directed towards protecting the enabling methods and technologies that makes it possible for us to develop innovations in a wide range of therapeutic and application areas.